Nutriband (NTRB) said Thursday that the company and Kindeva Drug Delivery have formalized their exclusive product development partnership for the Aversa Fentanyl abuse deterrent patch.
The companies have also formalized their long-term commitment based on shared development costs in exchange for milestone payments.
Nutriband's Aversa technology can be used to incorporate aversive agents into transdermal patches to prevent the abuse and accidental exposure of drugs with abuse potential, including opioids and stimulants.
The company's shares were up 3.1% in recent trading.
Price: 7.34, Change: +0.22, Percent Change: +3.09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.